Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15308902 | 0.89 | F2 (0.49) | KLKB1 | |
| SCHEMBL14486111 | 0.85 | KLKB1 (0.78) | KLKB1KLK1 | |
| SCHEMBL10056562 | 0.84 | CA1 (0.49) | KLKB1 | |
| SCHEMBL15308907 | 0.82 | F2 (0.51) | KLKB1 | |
| SCHEMBL14485469 | 0.79 | KLKB1 (0.62) | KLKB1KLK1 | |
| Benzene SCHEMBL14486117 | 0.76 | KLKB1 (0.79) | KLKB1KLK1 | |
| SCHEMBL14554987 | 0.76 | KLKB1 (0.79) | KLKB1KLK1 | |
| SCHEMBL14485480 | 0.76 | KLKB1 (0.76) | KLKB1KLK1 | |
| SCHEMBL14823093 | 0.75 | F2 (0.75) | KLKB1 | |
| SCHEMBL14485341 | 0.75 | KLKB1 (0.76) | KLKB1KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921319-B2 | Serine protease inhibitors | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2014-12-30 | — | — | US | disclosed |
| EP-2590945-B1 | SERINE PROTEASE INHIBITORS | MEDICINES CO LEIPZIG GMBH (DE) | 2014-04-30 | — | — | EP | disclosed |
| US-20130267467-A1 | SERINE PROTEASE INHIBITORS | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2013-10-10 | — | — | US | disclosed |
| WO-2012004678-A2 | SERINE PROTEASE INHIBITORS | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267467-A1 | SERINE PROTEASE INHIBITORS | SERPINE1, KLKB1, SERPINC1 | KLKB1 2/4885KLK1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.